At the news
? BULLISHIMPACT 7/10 425 filed Jul 20, 2026 at 17:16 ET
Tempus AI (TEM) has entered into a definitive merger agreement to acquire Personalis, Inc. in a stock-for-stock transaction valued at an implied $16.25 per Personalis share, with Tempus retaining the option to pay cash for up to 50% of shares. The deal brings Personalis's molecular residual disease (MRD) technology into Tempus's AI-enabled precision oncology platform, targeting a $20B market opportunity. Closing is expected by April 2027, subject to Personalis shareholder approval, HSR clearance, and other customary conditions.
- Per-share consideration: $16.25 cash option or stock based on floating exchange ratio with floor at $48.42 TEM stock price
- Termination fee: ~$76.8M payable by either party under specified conditions
- Personalis has a termination right if TEM stock falls below $46.00
- Transaction structured as tax-free reorganization under Section 368(a) of the Code
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access